FLGT — Fulgent Genetics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapSuper Stock

Annual cashflow statement for Fulgent Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	214	506	142	-175	-43.8
Depreciation
Deferred Taxes
Non-Cash Items	16.6	32.2	85.2	162	50.9
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-91.5	-2.68	2	2.84	-7.24
Change in Accounts Receivable
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Cash from Operating Activities	141	539	254	27	21.1
Capital Expenditures	-35.1	-23.8	-18.8	-22.2	-40.3
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-291	-523	-243	61.1	-18
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-326	-547	-261	38.9	-58.4
Financing Cash Flow Items	—	0.01	0	0	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	261	85.4	-77.1	-47.8	-4.85
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	75.5	77.5	-85.4	18	-42.2